Skip to main content
SpringerLink
Log in

Translating Nitric Oxide Research to Therapeutics: A Critical Appraisal

  • Chapter
  • First Online:
Nitric Oxide: From Research to Therapeutics

Part of the book series: Advances in Biochemistry in Health and Disease ((ABHD,volume 22))

  • 359 Accesses

Abstract

Nitric oxide (NO) is a signaling molecule with an extensive range of functions in both health and disease. Initially proposed as a regulator of cardiovascular function, the significance of NO has now been realized in the neurological, hematological and immune systems. Recent research has indicated complex roles for NO in skeletal muscle, myocardium, metabolic effects like insulin signaling, neurotransmission and cancer biology. Its emerging role as a gasotransmitter and interactions with other reactive molecules has been in the limelight and both pro and antioxidant effects are proposed. Regulation of NO production is determined by numerous factors including arginine bioavailability, co-factors and expression of endogenous regulators. Low (physiological) levels of NO are mostly protective, whereas high levels tend to be toxic. Mitochondria is also the site for the life-threatening deleterious effects arising from inflammation-related excessive NO levels. NO-deficient states are characterized by cell senescence, oxidative stress, inflammation, endothelial dysfunction and insulin resistance. In sepsis, NO synthesis is dysregulated leading to cardiovascular dysfunction, bioenergetic failure and cellular toxicity. NO-enriching therapy may be of benefit not only for its hemodynamic but also for its metabolic impact as well as other effects. In contrast, strategies are needed to curtail excessive NO in states such as septic shock. Thus, both lack and excess of NO production can have various important implications in which dietary factors can play a modulating role. Future research is needed to expand our understanding of the regulation of NO production at the organ level and by the different NOS isoforms. An innovative bench to bedside approach will facilitate the translation of these biological effects at cellular/tissue levels for clinical benefits. Both nutritional and pharmacological approaches are being increasingly adopted to device novel therapeutic strategies by modulating NO levels/activity for several critical pathophysiological conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43(2):109–142

    Google Scholar 

  2. Davis KL, Martin E, Turko IV, Murad F (2001) Novel effects of Nitric Oxide. Ann Rev PharmacolToxicol 41:203–223

    Article  CAS  Google Scholar 

  3. Moncada S, Higgs EA (2006) The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 147:S193–S201. https://doi.org/10.1038/sj.bjp.0706458

  4. Levine AB, Punihaole DT, Levine TB (2012) Characterization of the role of nitric oxide and its clinical applications. Cardiology 122:55–68. https://doi.org/10.1159/000338150

    Article  CAS  PubMed  Google Scholar 

  5. Ray A, Chakraborti A, Gulati K (2007) Current trends in nitric oxide research. Cell MolBiol 53:3–14

    CAS  Google Scholar 

  6. Lundberg JO, Weitzberg E, Gladwin MT (2008) The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7:156–167

    Google Scholar 

  7. Luiking YC, Engelen MPKJ, Deutz NEP (2010) Regulation of nitric oxide production in health and disease. Curr Opin Clin Nutr Metab Care 13(1):97–104. https://doi.org/10.1097/MCO.0b013e328332f99d

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lambden S (2019) Bench to bedside review: therapeutic modulation of nitric oxide in sepsis—an Update. Intensiv Care Med Exp 7:1–14. https://doi.org/10.1186/s40635-019-0274-x

  9. Pernow J, Jung C (2013) Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res 98:334–343. https://doi.org/10.1093/cvr/cvt036

    Article  CAS  PubMed  Google Scholar 

  10. Demchenko SA, Koklin IS, Koklina NY (2020) Role of Arginase 2 as a potential pharmacological target for the creation of new drugs to correct cardiovascular diseases. Res Resuts Pharmacol 6(1):47–55. UDC: 611.018.74:615.256.4. https://doi.org/10.3897/rrpharmacology.6.50942

  11. Wijnands KAP, Hoeksema MA, Meesters DM, van den Akker NMS, Molin DGM, Briedé JJ et al (2014) Arginase-1 deficiency regulates arginine concentrations and nos2-mediated no production during endotoxemia. PLOS ONE https://doi.org/10.1371/journal.pone.0086135

  12. Cooke JP (2004) Asymmetrical dimethylarginine: the Über marker? Circulation 109:1813–1818. https://doi.org/10.1161/01.CIR.0000126823.07732.D5

    Article  PubMed  Google Scholar 

  13. Sibal L, Agarwal SC, Home PD, Boger RH (2010) The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 6(2):82–90

    Google Scholar 

  14. Tsikas D, Bollenbach A, Hanff E et al (2018) Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA SDMA and hArg paradoxes. Cardiovasc Diabetol 17:1. https://doi.org/10.1186/s12933-017-0656-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Watson CP, Pazarentzos E, Fidanboylu M, Padilla B, Brown R, Thomas SA (2016) The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood–brain barrier in vitro. Brain Res 1648:232–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Fiedler L (2008) The DDAH/ADMA pathway is a critical regulator of NO signalingin vascular homeostasis. Cell AdhesMigr 2:149–150

    Google Scholar 

  17. Leiper J, Nandi M (2011) The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 10:277–291

    Article  CAS  PubMed  Google Scholar 

  18. Luiking YC, Ten Have GAM, Wolfe RR, Deutz NEP (2012) Arginine de novo and nitric oxide production in disease states. Am J Physiol Endocrinol Metab 303(10):E1177–E1189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gambardella J, Khondkar W, Morelli1 M, Wang X, Santulli G, Trimarco V (2020) Arginine and endothelial function. Biomedicines 8, 277:1–24. https://doi.org/10.3390/biomedicines 8080277

  20. Allerton TD, Proctor DN, Stephens JM, Dugas TR, Spielmann G, Irving BA (2018) l-Citrulline supplementation: impact on cardiometabolic health. Nutrients 10(7):921. https://doi.org/10.3390/nu10070921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Palencia JYP, Saraiva A, Abreu MLT1, Zangeronimo MG, Schincke AP, Garbossa CAP Effectiveness of citrulline and N-carbamoyl glutamate as arginine precursors on reproductive performance in mammals: a systematic review. PLOS ONE 13(12):e0209569. https://doi.org/10.1371/journal.pone.0209569

  22. Farah C, Michel LYM, Balligand JL (2018) Nitric oxide signalling in cardiovascular health and disease. Nature Rev Cardiol 15:292–316

    Article  CAS  Google Scholar 

  23. Liu VWT, Huang PL (2008) Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 77:19–29. https://doi.org/10.1016/j.cardiores.2007.06.024

  24. Förstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33:829–837. https://doi.org/10.1093/eurheartj/ehr304

    Article  CAS  PubMed  Google Scholar 

  25. Zhao Y, Vanhoutte PM, Leung SWS (2015) Vascular nitric oxide: beyond eNOS. J Pharmacol Sci 129:83–94

    Google Scholar 

  26. McRae MP (2016) Therapeutic benefits of L-arginine: an umbrella review of meta-analyses. J Chiropr Med 15:184–189

    Google Scholar 

  27. Wu G, Meininger CJ, Knabe DA, Bazer FW, Rhoads JM (2000) Arginine nutrition in development, health and disease. Curr Opin Clin Nutr Metab Care 3(1):59–66. https://doi.org/10.1097/00075197-200001000-00010

  28. Rashid J, Kumar SS, Job KM, Liu X, Fike CD, Sherwin CM (2020) Therapeutic potential of citrulline as an arginine supplement: a clinical pharmacology review. Paediatr Drugs 22(3):279–293. https://doi.org/10.1007/s40272-020-00384-5

    Article  PubMed  PubMed Central  Google Scholar 

  29. Khan A, Dawoud H, Malinski T (2018) Nanomedical studies of the restoration of nitric oxide/peroxynitrite balance in dysfunctional endothelium by 1,25-dihydroxy vitamin D3—clinical implications for cardiovascular diseases. Int J Nanomed 13:455–466

    Google Scholar 

  30. Oral O (2021) Nitric oxide and its role in exercise physiology. J Sports Med Phys Fitness 61(9):1208–1211. https://doi.org/10.23736/S0022-4707.21.11640-8

    Article  PubMed  Google Scholar 

  31. Das P, Lahiri A, Lahiri A, Chakravortty D (2010) Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator. PLoS Pathog 6:1–7

    Google Scholar 

  32. Bath PM, Coleman CM, Gordon AL, Lim WS, Webb AJ (2021) Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections [version 2; peer review: 1 approved]. F1000Research. 10:536. https://doi.org/10.12688/f1000research.51270.2

  33. Mintz J, Vedenko A, Rosete O, Shah K, Goldstein G , Hare JM, Ramasamy R, Arora H (2021) Current advances of nitric oxide in cancer and anticancer therapeutics. Vaccines 9:94. https://doi.org/10.3390/vaccines9020094

  34. KordeChoudhary S, Chaudhary M, Bagde S, Gadbail AR, Joshi V (2013) Nitric oxide and cancer: a review. World J SurgOnc 11:118. https://doi.org/10.1186/1477-7819-11-118

    Article  Google Scholar 

  35. Gulati K, Joshi JC, Ray A (2015) Recent advances in stress research: focus on nitric oxide. Europ J Pharmacol. 765:406–414

    Article  CAS  Google Scholar 

  36. Dubey H, Gulati K, Ray A (2018) Ameliorative effects of s-nitrosoglutathione (NO donor) on intracerebroventricular streptozotocin induced neurobehavioral and biochemical changes in rats. Neuro Toxicol 66:58–65

    Google Scholar 

  37. Hollenberg SM, Cinel I (2009) Bench-to-bedside review: nitric oxide in critical illness–update 2008. Crit Care 13:218. https://doi.org/10.1186/cc7706

    Article  PubMed  PubMed Central  Google Scholar 

  38. Tremblay J, Couture EJ, Albert M, Beaubien-Souligny W, Elmi-Sarabi M, Lamarche Y, Denault AY (2019) Noninvasive administration of inhaled nitric oxide and its hemodynamic effects in patients with acute right ventricular dysfunction. J Cardiothorac Vasc Anesth 33(3):642–647. https://doi.org/10.1053/j.jvca.2018.08.004

    Article  CAS  PubMed  Google Scholar 

  39. Martel J, Ko YF, Young JD, Ojcius DM (2020) Could nasal nitric oxide help to mitigate the severity of COVID-19?. Microbes Infect 22:168–171. https://doi.org/10.1016/j.micinf.2020.05.002

  40. Ricciardolo FLM, Bertolini F, Carriero V, Högman M (2021) Nitric oxide’s physiologic effects and potential as a therapeutic agent against COVID-19. J Breath Res 15:014001. https://doi.org/10.1088/1752-7163/abc302

  41. Lotz C, Muellenbach RM, Meybohm P, Mutlak H, Lepper PM, Caroline-Barbara CB et al (2021) Effects of inhaled nitric oxide in COVID-19-induced ARDS—Is it worthwhile? Acta Anaesthesiol Scand 65(5):629–632. https://doi.org/10.1111/aas.13757. Epub 2020 Dec 20

  42. de Mel A (2020) Potential roles of nitric oxide in COVID-19: a perspective. IntegrMol Med 7. https://doi.org/10.15761/IMM.1000403

  43. Mir JM, Maurya RC (2021) Nitric oxide as a therapeutic option for COVID-19 treatment: a concise perspective. New J Chem 45:1774–1784

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pharmacology, Hamdard Institute of Medical Sciences and Research (HIMSR), Hamdard University, New Delhi, India

    Arunabha Ray & Sana Rehman

  2. Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India

    Kavita Gulati

Authors
  1. Arunabha Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kavita Gulati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sana Rehman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arunabha Ray .

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Hamdard Institute of Medical Sciences and Research, Hamdard University, New Delhi, India

    Arunabha Ray

  2. Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India

    Kavita Gulati

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ray, A., Gulati, K., Rehman, S. (2023). Translating Nitric Oxide Research to Therapeutics: A Critical Appraisal. In: Ray, A., Gulati, K. (eds) Nitric Oxide: From Research to Therapeutics. Advances in Biochemistry in Health and Disease, vol 22. Springer, Cham. https://doi.org/10.1007/978-3-031-24778-1_1

Download citation

Publish with us

Policies and ethics

Search

Navigation